IL33 and cancer: PD-1-driven regulation of IL-9 production by ILC2s may be relevant in cancer as PD-1+ ILC2s were detected in human cancer, and PD-1 blockade in combination with IL-33 enhanced the anti-tumor function of ILC2s [49].